Archive for the ‘Psychological Aspects’ Category

Government Neuroweapons & Undetectable Illness (Is Lyme/MSIDS One?)

https://gregreese.substack.com/p/targeted-individuals  Video Here (Approx. 6 Min)

Targeted Individuals

The US government has been targeting thousands of innocent civilians for decades

GREG REESE

SEP 5, 2023
Excerpts:

Targeted Justice dot com is currently working on suing the federal government for targeting individual US citizens with different high-tech weapons including Directed Energy Weapons. The Havanna syndrome, when diplomats in Cuba were attacked with Directed Energy Weapons, was not an isolated event. There are thousands of individuals who claim to be under this same sort of attack. And they have the scars to prove it.

As far back as 1976, the technology to remotely alter brain waves has existed. Including Voice to Skull technology that allows the government to directly transmit voices into people’s brains.

As bad as all this is, it is likely to get much worse. In 2017 Dr James Giordano gave a lecture on the latest government technologies to target individuals. Such as neuroweapons to control brain function and modify memories. Nano particulates that can give an individual a stroke. He explains how they can make people sick with an undetectable illness to make them go crazy. And he says they can already control insects and use them to deliver bioweapons.

(See link for article and video)

_________________

http://

The Brain is the Battlefield of the Future

Dr. James Giordano

July 3, 2023

**Comment**

If you don’t have time to view the lengthy video, at least watch the brief 6 minute one in the top link.  Relevant snippets have been pulled that you need to hear.

http://

Directed Energy Weapons

DOD spends about $1 billion annually on directed energy—concentrated electromagnetic energy—weapons, including high energy lasers and high powered microwaves. DOD has pursued these potentially transformative technologies for decades because they could provide considerable advantages. They can deliver destructive or disruptive effects to targets at the speed of light and have potentially significant advantages over kinetic weapons, such as guns and missiles, including lower per-use cost.

Speaking of targeting civilians, recently Hawaii was hit with fires that defy explanation. Let’s review the events:
  1.  No fire sirens were sounded – intentionally.
    The Head of the Maui Emergency Agency, who made this decision, resigned for “health reasons.”
  2. A state official refused to release water to fight the fires and officials are accused of preventing access to water.  Deputy director Kaleo Manuel, linked the the Obama Foundation, and known for his stance on water “equity,” has since been “reassigned” amid accusations of a delayed response that led to death and destruction.
  3. Despite fire warnings, Hawaiian Electric didn’t shut off power to reduce fire potential.
  4. Maui Police Chief John Pelletier who has top FBI clearance and was involved in ethics complaints resulting in an investigation, just happened to be the incident commander in Las Vegas during the horrific 2017 mass shooting.  I mean, what are the odds?
  5. Police put up barricades causing a gridlock and death. Those who disobeyed the road closures survived.

In fact, the entire event is shrouded in bizarre and inexplicable events, until you hear Hawaii Governor Josh Green stating there will be deadly fires “month in and month out” all across the country and that in an effort to “build back better,” the “state will acquire properties as a memorial and for workforce housing.”

It shouldn’t come as a surprise that a blackout fence is being built around the entire town. Somehow we are supposed to believe that wild fires selectively burn some houses and not others, and leave whole trees standing while everything in their path is reduced to ashes.  A book was published about the Maui fires just two days after the brunt of the fires were over.  I highly recommend “What the Media Won’t Tell You About the Maui Fires,” with eye-witness accounts.  I also recommend “A Guide to Understanding the Hoax of the Century.”

Again, things are not as they seem. 

For more:

Category:

Activism, Lyme, Psychological Aspects, Ticks

New Treatment Options For Chronic Lyme Patients

https://www.lymedisease.org/members/lyme-times/2023-summer-features/new-treatments-chronic-lyme-disease/

New treatment options for chronic Lyme patientsNovel therapeutic protocols offer hope for complex cases.

By Dr. Steve Harris
 
Summer, 2023
 
Summary:
  • Dr. Mike Snyder’s group at Stanford is working on multiomics for chronic fatigue that track an individual patient’s data. This will help Lyme/MSIDS patients because treatments need to be individualized as each case is different.
  • Mitochondrial work is going to become bigger because illness and wellness is fundamentally all about energy.  Detoxing and absorbing nutrients will help the body function effectively without much external intervention.
  • Unique modalities like growth hormone, DHEA, and metformin are being used to decrease the age of cells to help the very complicated group of patients who are not getting better on standard treatments.
  • Regenerative therapies including exosomes, PRP, and alpha 2-macroglobulin, among others are also helpful for tendon issues, osteoarthritis and orthopedics but exosomes have been used in parallel to stem cell therapies which is written about in a book by Amy Scher titled, This is How I Save My Life.  She wrote about her journey through India, where she received human embryonic stem cells, and went from a very severe neurologic case of Lyme to being quite well now. 
  • Jaw misalignment, spinal issues, and craniocervical instability (all related to body structure) needs to be addressed due to the severe inflammation Lyme/MSIDS patients have.
  • Trauma needs to be addressed but often requires a circuitous approach such as the Dynamic Neural Retraining SystemTM (DNRS), vagus nerve training, neurofeedback, neuro stimulation, and various other methods.  A scientist in Wisconsin, Yuri Danilov, developed the PoNS device, which is a tongue neurostimulation device owned by a company called Helius Medical technologies. It is FDA approved for head trauma but it also works for PTSD.  They’re trying to get FDA approval and they are making it available to physical therapists. It’s mentioned in Dr. Norman Doidge’s book The Brain’s Way of Healing. Some patients have had  phenomenal results using it.
  • The onion parable is used to explain the importance of peeling back layer after layer of issues an individual has – and recognizing that being infected with Lyme and/or the various coinfections is only one layer in this complex puzzle.  Typically these onslaughts alone are not the problem, but the cumulative effect of multiple onslaughts is what makes us sick.
  • Viruses, which are becoming more of a problem, are opportunistic and cause the body to decompensate.  Again, treating them singularly usually isn’t the answer, but they are important to consider in the overall picture.
  • mTOR Agents and Autophagy:  Dr. Steven Phillips uses mTOR agents, (mammalian target of Rapamycin) to increase one’s autophagy (cleans the body of debris).  Honokiol (magnolia leaf), doxycycline, methylene blue, vitamin D, and other agents increase autophagy.
  • Toxic load, nutrient status, and environmental stressors:  using different kinds of fats helps patients through membrane chemistry to flush out debris in the lipid bilayer on the surface of cells.  Many things cause patients to be overreactive and dealing with it is very important.

“In conclusion, these are a few different ways to address this most complicated, most difficult group of patients. I truly believe that everybody can get better, and I think that sharing that hope with the patient is a way for them to be able to hold on during what is a marathon for many of them. Not everybody needs to take every step, but the steps are there, and it can be done.” — Dr. Steven Harris

(See link for article)

__________________

For more:

Category:

Chiropractic Care for MSIDS, Detoxing, diet and nutrition, Herbs, Lyme, Psychological Aspects, Treatment, Viruses

Living Well When You Don’t Feel Well: Overcoming Lyme Disease & Illness

http://  Approx. 18 Min

Living Well When You Don’t Feel Well

Overcoming Lyme Disease & Illness

Joe Trunzo PhD Professor of Psychology

Dr. Trunzo highlights a different way of thinking and coping with diseases (and life), specifically Lyme disease. 

He earned his undergraduate degree in 1993 from Marywood University in Scranton PA and completed his graduate work in 2000 at Drexel University in Philadelphia, PA. He completed his pre-doctoral internship at the University of Vermont and his post-doctoral fellowship at the Centers for Behavioral & Preventive Medicine at Brown University Medical School in Providence, RI. He is a Professor of Psychology and Chair of the Department of Applied Psychology at Bryant University. He is also a licensed, practicing clinical psychologist with expertise in the psychological management of chronic medical illnesses such as cancer and Lyme disease, as well as the treatment of mood and anxiety disorders, especially obsessive compulsive disorder. He serves on several professional committees and belongs to a number of professional organizations. In his spare time, he enjoys being with his family, live music, running, and mountain climbing.

This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx

_______________

**Comment**

A very sane and logical talk on the Lyme/MSIDS controversy involving three camps of thought, which then moves on into how to develop a mindset that focuses on living the best life you can while sick.  Dr. Trunzo utilizes the mindfulness based, values-oriented behavioral therapy called ACT (Acceptance & Commitment Therapy) to help patients.

He states that by not accepting what patients are feeling and going through, they can trap themselves and create more problems.  I must throw in a personal note here: one of the most helpful things I was ever told early on by another patient who reached the other side was:

“Don’t be depressed about feeling depressed.”

This may be laughingly simple; however, I found that I needed to give myself permission to feel depressed.  Knowing, understanding and accepting the fact I was going to feel miserable and have some really rotten days (or months!) helped me tremendously.  Being chronically/persistently infected with multiple pathogens that work symbiotically and that are in your brain and virtually every organ of your body wreaking havoc, not only affects you physically but emotionally and spiritually.  Add in the fact that mainstream medicine denies this fact entirely and that your friends and family may choose to believe you are a hypochondriac rather than an extremely ill person who needs help, because after-all you “look fine” – and you can become very depressed and isolated indeed, which doesn’t help the healing process at all!

Obviously, the goal here is not to remain sick, but to achieve wellness and health; however, with Lyme/MSIDS that may take years to accomplish, and even then there is a very real potential that facets of your health may never return to the way they were before you became infected.  As with all things in Lymeland, everyone’s journey is unique to them and no two cases look alike.

For more:

Category:

Lyme, Psychological Aspects, Treatment

Suicidal & Homicidal Lyme Concerns Podcast

https://danielcameronmd.com/suicidal-and-homicidal-lyme-concerns/

SUICIDAL AND HOMICIDAL LYME CONCERNS

Suicidal and homicidal Lyme concerns

Welcome to another selection from my book “An Expert’s Guide on Navigating Lyme disease.” The books highlights the findings of my first 600 Lyme disease Science blogs.  In this episode, I will discuss suicidal and homicidal concerns in Lyme disease patients.

By 

Dr. Robert Bransfield from Rutgers-Robert Woods Johnson Medical School, Department of Psychiatry, has described suicidal and homicidal concerns in patients with Lyme and related tick-borne illnesses in his private practice. Likewise, in my practice I have seen patients with suicidal thinking.

SUICIDAL AND HOMICIDAL BEHAVIORS IN LYME DISEASE.

Dr. Robert Bransfield reports observing suicidal and homicidal behaviors in patients with Lyme and related tick-borne illnesses. Out of 253 patients, he found:

43% were suicidal; 32% were suicidal but not homicidal; 11% were both suicidal and homicidal. No patient was homicidal without also being suicidal. 25% had explosive anger but were not homicidal or suicidal. 10% had pre-existing depression. 97% reported depression after infection. Patients were ill an average of 8.4 years before being diagnosed and treated. Read more.

“Further disease progression contributed to him feeling desperate as a result of multiple late-stage symptoms.”

THREE PSYCHIATRISTS SHARE SUICIDAL AND HOMICIDAL CASES.

Three psychiatrists share published case reports supporting Bransfield’s concerns (Munir et al., 2017). “A 44-year-old male without any past psychiatric history presented with a third unsuccessful suicide attempt and was later diagnosed as having a Borrelia infection” (Bransfield, 2017). One month of medical therapy with intravenous ceftriaxone improved his mental status and resolution of suicidal ideation (Banerjee 2013).

Fallon described two cases in a 1995 paper. “I treated both of these patients, and in addition, I have been able to follow the status of Patient B over a span of 30 years. This patient was highly suicidal, had horrific intrusive images of killing others, and had violent impulses, which were eliminated with treatment. Patient A was also suicidal, violent, and physically assaultive to her son. Combined antibiotic and psychotropic treatment helped both patients.” Read more.

HOMICIDE, TWO ASSAULTS, AND SUICIDE IN LYME DISEASE PATIENT

An article entitled “A Fatal Case of Late Stage Lyme Borreliosis and Substance Abuse,” describes a patient exhibiting aggressiveness, violence, and homicidality. Like many Lyme disease patients, the man experienced a delay in diagnosis and treatment. (One study reports that subjects enrolling in a trial of Lyme encephalopathy were ill an average of two years before being diagnosed.)

The patient’s Lyme disease symptoms progressed. “Further disease progression contributed to him feeling desperate as a result of multiple late-stage symptoms,” wrote Bransfield et al.  According to Fallon et al., the number of Lyme disease patients who feel desperate is not clear.

Based on more than 30 years of experience treating Lyme disease patients, Dr. Bransfield previously described a wide range of neuropsychiatric symptoms in Lyme disease patients. “… neuropsychiatric symptoms, usually presenting with significant comorbidity which may include developmental disorders, autism spectrum disorders, schizoaffective disorders, bipolar disorder, depression, anxiety disorders (panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder, intrusive symptoms), eating disorders, decreased libido, sleep disorders, addiction, opioid addiction, cognitive impairments, dementia, seizure disorders, suicide, violence, anhedonia, depersonalization, dissociative episodes, derealization and other impairments.”

“A 44-year-old male without any past psychiatric history presented with a third unsuccessful suicide attempt and was later diagnosed as having a Borrelia infection.”

The patient’s condition worsened.  “The pathophysiological effects of the infection resulted in an increased number and severity of multisystem symptoms, disability, and substance abuse,” the authors wrote. “He experimented with multiple substances in an effort for relief.”

The authors added, “During acute deterioration of his mental state from phencyclidine withdrawal, NMDA agonism increased, he committed a homicide, two assaults, and suicide.”

In an earlier study, Dr. Bransfield described substance abuse, cannabis use, and intoxication in Lyme disease patients.

Bransfield and colleagues advised prompt diagnosis and treatment of Lyme disease to help prevent addictive disorders, substance abuse, and death.

“More effective diagnosis and treatment and attention to substance abuse potential in these patients may help prevent some cases of addictive disorders, substance abuse, and death.” Read more.

988 Suicide & Crisis Lifeline

The 988 Suicide & Crisis Lifeline is a national network of local crisis centers that provides free and confidential emotional support to people 24 hours a day, 7 days a week in the United States. Anyone with the following concerns can call, text, or chat 988:

  • Mental health-related distress.
  • Thoughts of suicide.
  • Substance use crisis.
  • Emotional distress.
  • There are specialized services available for veterans, LGBTQ individuals and other groups.
  • People who are worried about a loved one who may need support also can call.
The 988 Suicide & Crisis Lifeline, available by simply dialing 988, is a 24-hour, toll-free, confidential suicide prevention helpline available to anyone in suicidal crisis or emotional distress. When someone calls the helpline, his or her call is routed to the nearest crisis center. The Lifeline’s national network, consisting of more than 250 local crisis centers, provides crisis counseling and mental health referrals day and night.
Related Articles:

Mental health in COVID-19 and Lyme disease patients

Lyme disease and depression

Lyme disease patients at risk for suicide

Category:

Lyme, Psychological Aspects, research

Can Microdoses of Psychedelics Effectively Treat Neuro-Lyme?

https://www.lymedisease.org/microdosing-psychedelics-lyme/

Can microdoses of psychedelics effectively treat neuro-Lyme?

Dr. Dan Kinderlehrer

By Daniel A Kinderlehrer, MD

Those of us dealing with Lyme disease are well aware that most symptoms reside in the musculoskeletal and nervous systems. And for many of us, the worst symptoms in the nervous system are neuropsychiatric. The severity of anxiety, panic attacks, depression, irritability and rage can be overwhelming.

Chronic tick-borne infections can also cause bipolar disease, addiction syndromes, eating disorders, obsessive compulsive disorder and psychosis.1-8 And of course, it is all compounded by impaired sleep, brain fog, fatigue and chronic pain, not to mention physician ignorance.

Neuroinflammation

It turns out that these mental health symptoms are primarily caused by inflammation from infection outside the nervous system.9

For example, kids with PANS—Pediatric Acute-onset Neuropsychiatric Syndrome—have infections in which antibodies to different microbes cross the blood brain barrier and attack the brain, resulting in severe mood and behavioral disturbances.10 A similar process occurs in adults with neuropsychiatric Lyme disease.11-13

There is increasing recognition that many mood disorders are linked to infections and autoimmune disorders, and the common link is neuroinflammation—brain on fire.14

It is no surprise that people with neuropsychiatric Lyme disease have elevated levels of inflammatory mediators including antineuronal antibodies, cytokines, chemokines and inflammatory lipoproteins.9  Think of neuropsychiatric Lyme disease as autoimmune inflammation of the brain. The primary legs of treatment are antimicrobials, psychotropic medications and anti-inflammatory agents. Ideally, an anti-inflammatory agent will decrease inflammation but not suppress immune function.

In March 2023, I published a report describing a patient with long standing Lyme disease, Babesia and Bartonella infections in which the primary symptoms were neuropsychiatric.15 He experienced anxiety with panic attacks, depression with suicidal ideation and sleeplessness.

These symptoms gradually came under control with appropriate treatment, but a change in his regimen resulted in a severe relapse. He could no longer tolerate even low dose antimicrobials without Herxheimer reactions, Zoloft was not helping and he could not tolerate Ativan for anxiety. In fact, any benzodiazepine increased his suicidality. That is when his daughter suggested he try microdosing.

A new approach: psychedelic microdosing

This is from the case study that I published:

After a 40-year prohibition in the US of lysergic acid diethylamide (LSD) and psilocybin, there has been renewed interest in their potential for therapeutic benefit. The preponderance of research in the past two decades has been in controlled clinical settings in which subjects are administered a single high dose of a hallucinogen while under the supervision of a therapist/guide. In 2018 the US Food and Drug Administration categorized psilocybin as ‘a breakthrough therapy’ in the treatment of depression, a designation the agency applies to drugs that in early trials demonstrate substantial improvement over existing treatments.16

There is compelling evidence that psilocybin has potential value in the treatment of some mental health conditions. Multiple studies have documented its effectiveness in patients with depression, anxiety syndromes, end of life anxiety, and suggested benefit in OCD and addiction disorders.17-23

Microdosing is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance on a regular basis. The intention of microdosing is to offer similar benefits to full dose psychedelic therapy, but without perceptual distortions, the need for clinical oversight, or the risk of a bad trip.” 24

Microdosing has become increasingly popular. In one online microdosing forum that was begun in 2013, the number of subscribers rose to 40,000 in 2018 and 219,000 in October 2022.25 LSD and psilocybin continue to be listed as schedule I controlled substances, meaning legally they have no accepted therapeutic value. Nevertheless, possession of psilocybin has been decriminalized in many US cities and is on the ballot of many states to be legalized in clinical therapeutic settings; Oregon and Colorado have already done so.26

No longer suicidal

The subject of my case history began microdosing three times weekly at doses one-fiftieth of a typical hallucinogenic journey. Within two days he was no longer suicidal and within two weeks he felt well. He continues to microdose and feels well three years later.

No wonder they call psilocybin magic mushrooms. It is a potent stimulator of serotonin and may also have some influence on dopamine.27 But what may be more crucial is its anti-inflammatory action. It significantly inhibits pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukins IL-1b, and IL-6, and cyclooxygenase-2 concentrations in human macrophage cells.28-30

It turns out that most mental health disorders are caused by neuroinflammation. That’s right: most patients with anxiety, depression, bipolar disorder and even psychosis have inflammation in their brains driving their mood disorders.31

Neuroinflammation in these patients may be caused by undiagnosed tick-borne infections, but there are multiple other drivers of inflammation. Autoimmune diseases such as lupus, Sjögrens syndrome, rheumatoid arthritis and multiple sclerosis are well documented causes of neuropsychiatric illness.32-37  Stress by itself can result in inflammatory conditions.38 People with childhood histories of adverse events such as physical or sexual abuse have an increased risk of autoimmune problems.39

Patients with PTSD—Post Traumatic Stress Disorder—don’t just have hypervigilance and anxiety disorders. They develop the same nervous, immune and endocrine system dysregulation as patients with persistent tick-borne infections and neuropsychiatric disease.40

The role of genetics

Meanwhile, genetics plays a significant role in the development of autoimmune conditions. Add to this epigenetic transmission that alters gene expression without changing the underlying DNA expression, and allows for trauma to be handed down from one generation to the next41—just ask children and grandchildren of Holocaust survivors.

Microdosing psilocybin holds the potential to help patients suffering from these mental health issues. Numerous studies suggest that microdosing is effective in the treatment of anxiety and depression.42-46 Unfortunately, these studies are not controlled and are reliant on subject reporting—it is impossible to separate benefits from placebo effect. We clearly need better research on microdosing.

Presently Johns Hopkins University is recruiting for a study in which patients with PTLDS—Post Treatment Lyme Disease Syndrome—are treated with full hallucinogenic doses of psilocybin under the supervision of a therapist/guide.47 These ‘journeys’ last four or more hours in controlled settings. I hope this research finds positive benefits of treatment, but full dose psilocybin treatment demands excessive resources that will never be available to most patients with Lyme.

Those of us with “Chronic Lyme” know that PTLDS is actually persistent infection with Borrelia burgdorferi complicated by the existence of co-infections resulting in systemic inflammation—it is an autoimmune illness.48 In a review of the physiological effects of psychedelics, the authors Caitlin Thompson and Attila Szabo “…propose that psychedelics hold the potential to attenuate or even resolve autoimmunity.”

The bottom line is that microdosed psilocybin may be an important adjunct to the treatment of mental illness. It is time that we find the resources to perform properly controlled double-blind investigations into the impact of microdosed psilocybin on patients with neuropsychiatric Lyme disease as well as those suffering from the ever-increasing numbers suffering from mental health disorders.

Click here to read the entire case report.

Dr. Daniel Kinderlehrer is an internal medicine physician in Denver, Colorado, with a practice devoted to treating patients with tick-borne illness. He is the author of  Recovery From Lyme Disease: The Integrative Medicine Guide to the Diagnosis and Treatment of Tick-Borne Illness.

References
  1. Bransfield RC. Neuropsychiatric Lyme Borreliosis: An Overview with a Focus on a Specialty Psychiatrist’s Clinical Practice. Healthcare (Basel). 2018 Aug 25;6(3):104. doi: 10.3390/healthcare6030104. PMID: 30149626; PMCID: PMC6165408.
  2. Bransfield RC. Lyme Disease, comorbid tick-borne diseases, and neuropsychiatric disorders. Psychiatr Times. 2007 Dec 1;24(14):59–61.
  3. Fallon BA, Nields JA, Burrascano JJ, et al. The neuropsychiatric manifestations of Lyme borreliosis. Psychiatr Q. 1992;63(1):95–117.
  4. Fallon BA, Nields JA. Lyme disease: a neuropsychiatric illness. Am J Psychiatry. 1994;151(11):1571–83. doi: 10.1007/BF01064684. PMID: 1438607.
  5. Fallon BA, Kochevar JM, Gaito A, Nields JA. The Underdiagnosis Of Neuropsychiatric Lyme Disease in Children And Adults. Psychiatr Clin N Am. 1998;21(3):693–703. doi: 10.1016/s0193-953x(05)70032-0.
  6. Bransfield RC. Aggressiveness, violence, homicidality, homicide, and Lyme disease. Neuropsychiatr Dis Treat. 2018 Mar 9;14:693-713. doi: 10.2147/NDT.S155143. PMID: 29576731; PMCID: PMC5851570.
  7. Mattingley DW, Koola MM. Association of Lyme Disease and Schizoaffective Disorder, Bipolar Type: Is it Inflammation Mediated? Indian J Psychol Med. 2015 Apr-Jun;37(2):243-6. doi: 10.4103/0253-7176.155660. PMID: 25969618; PMCID: PMC4418265.
  8. Greenberg R. Tick-borne infections and pediatric bipolar disorder.  Psychiatry Brain Res. 2015;22:11. doi: 10.1016/j.npbr.2015.12.025.
  9. Bransfield RC. The psychoimmunology of lyme/tick-borne diseases and its association with neuropsychiatric symptoms. Open Neurol J. 2012;6:88-93. doi: 10.2174/1874205X01206010088. Epub 2012 Oct 5. PMID: 23091569; PMCID: PMC3474947.
  10. Chang K, Frankovich J, Cooperstock M, et al; PANS Collaborative Consortium. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. J Child Adolesc Psychopharmacol. 2015 Feb;25(1):3-13. doi: 10.1089/cap.2014.0084. Epub 2014 Oct 17. PMID: 25325534; PMCID: PMC4340805.
  11. Coughlin JM, Yang T, Rebman AW, et al. Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. J Neuroinflammation. 2018 Dec 19;15(1):346.
  12. Chandra A, Wormser GP, Klempner MS, et al. Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain Behav Immun. 2010;24(6):1018–24.
  13. Fallon BA, Stobino B, Reim S, Stoner J, Cunningham MW. Anti-lysoganglioside and other anti-neuronal antibodies in post-treatment Lyme disease and erythema migrans after repeat infection. Brain Behav Immun. 2020;2:100015.
  14. Benros ME, Waltoft BL, Nordentoft M, et al. Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders: A Nationwide Study. JAMA Psychiatry.2013;70(8):812–820. doi:10.1001/jamapsychiatry.2013.1111.
  15. Kinderlehrer DA. The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study. Int Med Case Rep J. 2023 Mar 3;16:109-115. doi: 10.2147/IMCRJ.S395342. PMID: 36896410; PMCID: PMC9990519.
  16. approval-priority-review/breakthrough-therapy (Accessed October 10, 2022)
  17. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021 May 1;78(5):481-489. doi: 10.1001/jamapsychiatry.2020.3285. Erratum in: JAMA Psychiatry. 2021 Feb 10;: PMID: 33146667; PMCID: PMC7643046.
  18. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006 Nov;67(11):1735-40. doi: 10.4088/jcp.v67n1110. PMID: 17196053.
  19. Khan AJ, Bradley E, O’Donovan A, Woolley J. Psilocybin for Trauma-Related Disorders. Curr Top Behav Neurosci. 2022;56:319-332. doi: 10.1007/7854_2022_366. PMID: 35711024.
  20. Bogadi M, Kaštelan S. A potential effect of psilocybin on anxiety in neurotic personality structures in adolescents. Croat Med J. 2021 Oct 31;62(5):528-530. doi: 10.3325/cmj.2021.62.528. PMID: 34730895; PMCID: PMC8596485.
  21. Yu CL, Yang FC, Yang SN, et al. Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis. Psychiatry Investig. 2021 Oct;18(10):958-967. doi: 10.30773/pi.2021.0209. Epub 2021 Oct 8. PMID: 34619818; PMCID: PMC8542741.
  22. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513. PMID: 27909165; PMCID: PMC5367557.
  23. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992. doi:1177/0269881114548296.
  24. Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Motives and Side-Effects of Microdosing With Psychedelics Among Users. Int J Neuropsychopharmacol. 2019 Jul 1;22(7):426-434. doi: 10.1093/ijnp/pyz029. PMID: 31152167; PMCID: PMC6600464.
  25. https://www.reddit.com/r/microdosing/ (Accessed October 10, 2022)
  26. https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2022/07/15/more-states-may-legalize-psychedelic-mushrooms (Accessed October 10, 2022)
  27. Coppola M, Bevione F, Mondola R. Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective? J Xenobiot. 2022 Feb 7;12(1):41-52. doi: 10.3390/jox12010004. PMID: 35225956; PMCID: PMC8883979.
  28. Nkadimeng SM, Steinmann CML, Eloff JN. Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells. J Inflamm Res. 2021 Aug 5;14:3729-3738. doi: 10.2147/JIR.S317182. PMID: 34385833; PMCID: PMC8352634.
  29. Kubera M, Maes M, Kenis G, et al. Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res. 2005 Apr 30;134(3):251-8. doi: 10.1016/j.psychres.2004.01.014. PMID: 15892984.
  30. Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018 Aug;30(4):363-375. doi: 10.1080/09540261.2018.1481827. Epub 2018 Aug 13. PMID: 30102081.
  31. Yuan, N., Chen, Y., Xia, Y. et al.Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Transl Psychiatry9, 233 (2019). https://doi.org/10.1038/s41398-019-0570-y
  32. Shen CC, Yang AC, Kuo BI, Tsai SJ. Risk of Psychiatric Disorders Following Primary Sjögren Syndrome: A Nationwide Population-based Retrospective Cohort Study. J Rheumatol. 2015 Jul;42(7):1203-8. doi: 10.3899/jrheum.141361. Epub 2015 May 15. PMID: 25979721.
  33. Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry. 2012 Jul;73(7):993-1001. doi: 10.4088/JCP.11r07425. Epub 2012 May 1. PMID: 22687742; PMCID: PMC9903299.
  34. Mura G, Bhat KM, Pisano A, Licci G, Carta M. Psychiatric symptoms and quality of life in systemic sclerosis. Clin Pract Epidemiol Ment Health. 2012;8:30-5. doi: 10.2174/1745017901208010030. Epub 2012 Apr 20. PMID: 22550545; PMCID: PMC3339425.
  35. Bernstein CN, Hitchon CA, Walld R, Bolton JM, Sareen J, Walker JR, Graff LA, Patten SB, Singer A, Lix LM, El-Gabalawy R, Katz A, Fisk JD, Marrie RA; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Jan 10;25(2):360-368. doi: 10.1093/ibd/izy235. PMID: 29986021; PMCID: PMC6391845.
  36. Lwin MN, Serhal L, Holroyd C, Edwards CJ. Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review. Rheumatol Ther. 2020 Sep;7(3):457-471. doi: 10.1007/s40744-020-00217-4. Epub 2020 Jun 13. PMID: 32535834; PMCID: PMC7410879.
  37. Silveira C, Guedes R, Maia D, Curral R, Coelho R. Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art. Psychiatry Investig. 2019 Dec;16(12):877-888. doi: 10.30773/pi.2019.0106. Epub 2019 Dec 9. PMID: 31805761; PMCID: PMC6933139.
  38. Calcia MA, Bonsall DR, Bloomfield PS, Selvaraj S, Barichello T, Howes OD. Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness. Psychopharmacology (Berl). 2016 May;233(9):1637-50. doi: 10.1007/s00213-016-4218-9. Epub 2016 Feb 5. PMID: 26847047; PMCID: PMC4828495.
  39. Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults. Psychosom Med. 2009 Feb;71(2):243-50. doi: 10.1097/PSY.0b013e3181907888. Epub 2009 Feb 2. PMID: 19188532; PMCID: PMC3318917.
  40. Bransfield RC. Adverse Childhood Events, Post-Traumatic Stress Disorder, Infectious Encephalopathies and Immune-Mediated Disease. Healthcare (Basel). 2022 Jun 17;10(6):1127. doi: 10.3390/healthcare10061127. PMID: 35742178; PMCID: PMC9222834.
  41. Yehuda R, Lehrner A. Intergenerational transmission of trauma effects: putative role of epigenetic mechanisms. World Psychiatry. 2018 Oct;17(3):243-257. doi: 10.1002/wps.20568. PMID: 30192087; PMCID: PMC6127768.
  42. Rootman JM, Kryskow P, Harvey K, et al. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Sci Rep. 2021 Nov 18;11(1):22479. doi: 10.1038/s41598-021-01811-4. PMID: 34795334; PMCID: PMC8602275.
  43. Lea T, Amada N, Jungaberle, H. Psychedelic microdosing: A subreddit analysis. Psychoactive Drugs. 2020;52:101-112. https://doi.org/10.1080/ 02791072.2019.1683260.
  44. Lea T, Amada N, Jungaberle H, et al. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Psychopharmacology. 2020;237:1521. https://doi.org/10.1007/s00213-020-05477-0.
  45. FadimanThe psychedelic explorer’s guide: Safe, therapeutic, and sacred journeys.  Simon and Schuster, New York, 2021.
  46. Johnstad PG. Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nordic Stud Alcohol Drugs. 2018; 35(1):39–51. https://doi.org/10.1177/1455072517753339
  47. https://classic.clinicaltrials.gov/ct2/show/NCT05305105 (Accessed June 30, 2023)
  48. Yehudina Y, Trypilka S. Lyme Borreliosis as a Trigger for Autoimmune Disease. Cureus. 2021 Oct 10;13(10):e18648. doi: 10.7759/cureus.18648. PMID: 34786243; PMCID: PMC8578812.
  49. Thompson C, Szabo A. Psychedelics as a novel approach to treating autoimmune conditions. Immunol Lett. 2020 Dec;228:45-54. doi: 10.1016/j.imlet.2020.10.001. Epub 2020 Oct 7. PMID: 33035575.

Category:

Inflammation, Lyme, Psychological Aspects, research, Sleep, Treatment